MX2017003640A - Receptores antigenicos quimericos. - Google Patents

Receptores antigenicos quimericos.

Info

Publication number
MX2017003640A
MX2017003640A MX2017003640A MX2017003640A MX2017003640A MX 2017003640 A MX2017003640 A MX 2017003640A MX 2017003640 A MX2017003640 A MX 2017003640A MX 2017003640 A MX2017003640 A MX 2017003640A MX 2017003640 A MX2017003640 A MX 2017003640A
Authority
MX
Mexico
Prior art keywords
chimeric antigen
antigen receptors
domains derived
receptors
tcr
Prior art date
Application number
MX2017003640A
Other languages
English (en)
Inventor
Macdonald Lynn
Mcwhirter John
Voronina Vera
Gurer Cagan
Tu Naxin
J Murphy Andrew
Thurston Gavin
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2017003640A publication Critical patent/MX2017003640A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Husbandry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

En la presente descripción se proporcionan métodos y composiciones relacionados con receptores antigénicos quiméricos (CAR) que tienen dominios de unión al antígeno derivados de una inmunoglobulina (Qg) y dominios constantes derivados de un receptor de linfocitos T (TCR).
MX2017003640A 2014-09-19 2015-09-18 Receptores antigenicos quimericos. MX2017003640A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462052947P 2014-09-19 2014-09-19
US201462052901P 2014-09-19 2014-09-19
US201462076836P 2014-11-07 2014-11-07
US201462094603P 2014-12-19 2014-12-19
US201562167650P 2015-05-28 2015-05-28
PCT/US2015/050975 WO2016044745A1 (en) 2014-09-19 2015-09-18 Chimeric antigen receptors

Publications (1)

Publication Number Publication Date
MX2017003640A true MX2017003640A (es) 2017-10-31

Family

ID=54261082

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003640A MX2017003640A (es) 2014-09-19 2015-09-18 Receptores antigenicos quimericos.

Country Status (13)

Country Link
US (1) US20160081314A1 (es)
EP (1) EP3193592A1 (es)
JP (1) JP2017529841A (es)
KR (1) KR20170083534A (es)
CN (1) CN107072184A (es)
AU (1) AU2015317370A1 (es)
BR (1) BR112017005245A2 (es)
CA (1) CA2959428A1 (es)
IL (1) IL250536A0 (es)
MX (1) MX2017003640A (es)
RU (1) RU2017113134A (es)
SG (1) SG11201701040XA (es)
WO (1) WO2016044745A1 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2971279B1 (en) 2013-03-15 2019-11-13 The Trustees of Princeton University Methods and devices for high throughput purification
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
CN105264127B (zh) 2013-03-15 2019-04-09 Gpb科学有限责任公司 颗粒的片上微流体处理
CN112094353A (zh) * 2014-03-05 2020-12-18 奥托路斯有限公司 具有针对T细胞受体beta恒定区的抗原结合域的嵌合抗原受体(CAR)
US11885807B2 (en) 2014-03-05 2024-01-30 Autolus Limited Method for depleting malignant T-cells
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
FR3029449B1 (fr) * 2014-12-03 2017-10-13 Pole De Plasturgie De Lest Dispositif de moulage pour la fabrication de pieces en materiau composite a partir de resine polymere liquide.
EP3232774B1 (en) * 2014-12-19 2019-10-09 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification through single-step multiple targeting
EP3461337A1 (en) 2015-05-06 2019-04-03 Snipr Technologies Limited Altering microbial populations & modifying microbiota
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
CA3001011A1 (en) * 2015-10-05 2017-04-13 Precision Biosciences, Inc. Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
DK3680329T3 (da) 2015-10-05 2021-08-23 Prec Biosciences Inc Modificerede meganukleaser med genkendelsesekvenser der findes i genet for den humane t-cellereceptor-alpha-konstantregion
AU2017240788B2 (en) 2016-04-01 2020-04-09 Amgen Inc. Chimeric receptors and methods of use thereof
IL303785A (en) 2016-04-01 2023-08-01 Kite Pharma Inc Chimeric antigen and T cell receptors and methods of use
JP7366543B2 (ja) 2016-04-01 2023-10-23 カイト ファーマ インコーポレイテッド Ｂｃｍａ結合分子及びその使用方法
US11377637B2 (en) 2016-04-15 2022-07-05 Memorial Sloan Kettering Cancer Center Transgenic T cell and chimeric antigen receptor T cell compositions and related methods
SG10201914014XA (en) * 2016-06-03 2020-03-30 Regeneron Pharma Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
EP3484284A1 (en) * 2016-07-12 2019-05-22 Kymab Limited Animals, cells, ligands, polypeptides & methods
WO2018039247A1 (en) * 2016-08-23 2018-03-01 The Regents Of The University Of California Proteolytically cleavable chimeric polypeptides and methods of use thereof
WO2018075586A1 (en) * 2016-10-18 2018-04-26 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof
KR102630036B1 (ko) 2016-12-23 2024-01-29 마크로제닉스, 인크. Adam9-결합 분자, 및 이것의 사용 방법
US20190359678A1 (en) * 2017-02-09 2019-11-28 The Regents Of The University Of California Chimeric t cell antigen receptors and methods of use thereof
TW201837175A (zh) 2017-03-13 2018-10-16 美商凱特製藥公司 用於黑色素瘤之嵌合抗原受體及其用途
EP3608335A4 (en) * 2017-04-05 2020-04-29 XDCExplorer (Shanghai) Co., Ltd. HUMANIZED ANTI-TPBG ANTIBODY, PRODUCTION METHOD THEREFOR, CONJUGATE THEREOF AND APPLICATIONS
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
JP2020529834A (ja) 2017-06-30 2020-10-15 プレシジョン バイオサイエンシズ，インク． Ｔ細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変ｔ細胞
WO2019028023A2 (en) 2017-07-31 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR EVALUATING CRISPR / CAS MEDIATED DISRUPTION OR EXCISION AND CRISPR / CAS INDUCED RECOMBINATION USING IN VIVO EXOGENIC DONOR NUCLEIC ACID
US11130999B2 (en) 2017-07-31 2021-09-28 Regeneron Pharmaceuticals, Inc. Cas-ready mouse embryonic stem cells and mice and uses thereof
WO2019046052A1 (en) 2017-09-01 2019-03-07 Gpb Scientific, Llc METHODS FOR PREPARING THERAPEUTICALLY ACTIVE CELLS USING MICROFLUIDIC
EP3684817A4 (en) 2017-09-22 2021-06-09 Wuxi Biologics Ireland Limited. NEW BIS SPECIFIC CD3 / CD19 POLYPEPTIDE COMPLEXES
MX2020003145A (es) * 2017-09-22 2020-07-29 Wuxi Biologics Ireland Ltd Nuevos complejos de polipeptidos biespecificos.
SG11202000771UA (en) 2017-09-29 2020-04-29 Regeneron Pharma Non-human animals comprising a humanized ttr locus and methods of use
EP3700924A4 (en) * 2017-10-27 2021-11-03 The Regents of the University of California TARGETED REPLACEMENT OF ENDOGENIC T-CELL RECEPTORS
WO2019099707A1 (en) 2017-11-16 2019-05-23 Kite Pharma, Inc Modified chimeric antigen receptors and methods of use
IL310006A (en) 2017-11-30 2024-03-01 Regeneron Pharma Non-human animals containing a humanized TRKB locus
EP3752599A1 (en) 2018-02-16 2020-12-23 Kite Pharma, Inc. Modified pluripotent stem cells and methods of making and use
AU2019239880B2 (en) 2018-03-19 2023-11-30 Regeneron Pharmaceuticals, Inc. Transcription modulation in animals using CRISPR/Cas systems
BR112020019026A2 (pt) * 2018-03-24 2020-12-29 Regeneron Pharmaceuticals, Inc. Animal não humano geneticamente modificado, métodos para produzir o animal não humano geneticamente modificado, para geração de uma proteína de ligação a antígeno, para obtenção de um ácido nucleico, e, para obtenção de uma célula que expressa um domínio variável de cadeia pesada de imunoglobulina humana e/ou um domínio variável de cadeia leve de imunoglobulina humana, método in vitro de produção de um domínio variável de imunoglobulina humana, ácido nucleico, célula hospedeira, célula isolada, e, domínio variável de cadeia pesada de imunoglobulina humana
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
CN108424931A (zh) * 2018-03-29 2018-08-21 内蒙古大学 CRISPR/Cas9技术介导山羊VEGF基因定点整合的方法
KR20240005139A (ko) 2018-04-12 2024-01-11 프리시젼 바이오사이언시스 인코포레이티드 인간 t 세포 수용체 알파 불변 영역 유전자에 대한 특이성을 갖는 최적화된 조작된 뉴클레아제
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
CA3177829A1 (en) 2018-12-12 2020-06-18 Kite Pharma, Inc. Chimeric antigen and t cell receptors and methods of use
TW202039543A (zh) * 2018-12-27 2020-11-01 國立大學法人京都大學 Ｔ細胞受體的變體
CN117178959A (zh) 2019-04-04 2023-12-08 瑞泽恩制药公司 包括人源化凝血因子12基因座的非人动物
EP3801011A1 (en) 2019-06-04 2021-04-14 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
BR112021022722A2 (pt) 2019-06-07 2022-01-04 Regeneron Pharma Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente
BR112021026831A2 (pt) * 2019-07-03 2022-02-22 Regeneron Pharma Proteínas de ligação ao antígeno anti-carcinoma de células escamosas esofágicas new york 1 (ny-eso-1) e métodos de uso das mesmas
EP3999081A1 (en) 2019-07-18 2022-05-25 GPB Scientific, Inc. Ordered processing of blood products to produce therapeutically active cells
EP4081344A1 (en) 2019-12-28 2022-11-02 GPB Scientific, Inc. Microfluidic cartridges for processing particles and cells
CN111320703A (zh) * 2020-03-11 2020-06-23 北京双赢科创生物科技有限公司 靶向cd22的嵌合抗原受体及其应用
WO2021190580A1 (en) * 2020-03-26 2021-09-30 Wuxi Biologics (Shanghai) Co., Ltd. Bispecific polypeptide complexes, compositions, and methods of preparation and use
CN114746152A (zh) * 2020-08-23 2022-07-12 应用干细胞有限公司 Hla-f修饰的细胞和方法
CN117615786A (zh) * 2021-05-07 2024-02-27 森蒂生物科学公司 嵌合抗原受体及其使用方法
EP4215042A1 (en) * 2022-01-21 2023-07-26 Max-Delbrück-Centrum für Molekulare Medizin A non-human mammal comprising in its genome at least two human leukocyte antigen (hla) class i alleles, methods of making such mammal and uses thereof
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
CN116138212B (zh) * 2023-01-11 2024-03-05 江苏省中医院 一种制备细胞因子释放综合征小鼠模型的方法及应用
CN118460446A (zh) * 2024-07-12 2024-08-09 内蒙古自治区农牧业科学院 一种支原体突变株及其制备方法与应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
JPS6463394A (en) * 1987-09-04 1989-03-09 Kyowa Hakko Kogyo Kk Novel chimera polypeptide
IL86278A (en) * 1988-05-04 2003-06-24 Yeda Res & Dev Endowing cells with antibody specificity using chimeric t cell receptor
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6045796A (en) 1992-12-17 2000-04-04 Anergen, Inc. Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease
US5512295A (en) 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
US6001349A (en) 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US7001614B2 (en) 1996-08-19 2006-02-21 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US6770291B2 (en) 1996-08-30 2004-08-03 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US7112338B2 (en) 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US6749863B1 (en) 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) * 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20090042291A1 (en) 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
WO2004058278A1 (en) 2002-12-16 2004-07-15 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant vaccine viruses expressing il-15 and methods of using the same
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US8218805B2 (en) 2003-10-11 2012-07-10 Charles Hornback Wireless speaker system for use with ceiling fans
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
ATE504599T1 (de) 2004-01-16 2011-04-15 Regeneron Pharma Zur aktivierung von rezeptoren fähige fusionspolypeptide
CA2567814C (en) 2004-05-27 2013-07-23 Jon A. Weidanz Antibodies as t cell receptor mimics, methods of production and uses thereof
CA2583750C (en) 2004-10-19 2015-11-24 Regeneron Pharmaceuticals, Inc. Methods for generating a rodent having a genetic modification
EP1810035A4 (en) 2004-11-10 2010-03-17 Macrogenics Inc EFFECTOR FUNCTION OBTAINED BY CREATION BY BIOLOGICAL GENE OF FC ANTIBODY REGIONS
WO2007001457A2 (en) 2004-11-12 2007-01-04 Xencor, Inc. Antibodies operably linked to selected chemoattractants
WO2006076594A2 (en) 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
US20070190063A1 (en) 2005-08-19 2007-08-16 Bahjat Keith S Antibody-mediated enhancement of immune response
TR201909609T4 (tr) 2005-08-23 2019-07-22 Univ Pennsylvania Modifiye edilmiş nükleosidleri içeren rna ve kullanım yöntemleri.
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
NZ584042A (en) 2007-10-18 2012-09-28 Bn Immunotherapeutics Inc Use of mva to treat prostate cancer
US8225343B2 (en) 2008-01-11 2012-07-17 Sony Computer Entertainment America Llc Gesture cataloging and recognition
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
EP3028564B2 (en) 2009-07-08 2024-01-24 Kymab Limited Animal models and therapeutic molecules
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
RS59001B1 (sr) 2010-02-08 2019-08-30 Regeneron Pharma Miš sa zajedničkim lakim lancem
WO2011120135A1 (en) 2010-03-29 2011-10-06 Zymeworks, Inc. Antibodies with enhanced or suppressed effector function
ME03386B (me) 2010-06-22 2020-01-20 Regeneron Pharma Hibridni laki lanac imunoglobulina koji ispoljavaju miševi
US8539547B2 (en) 2010-08-18 2013-09-17 Certes Networks, Inc. Policy selector representation for fast retrieval
DK2738259T3 (da) 2011-02-25 2020-02-17 Regeneron Pharma ADAM6-mus
JP5893258B2 (ja) 2011-03-31 2016-03-23 フェリカネットワークス株式会社 情報処理装置および方法、並びにプログラム
CN104039133B (zh) 2011-10-28 2018-05-04 瑞泽恩制药公司 表达嵌合主要组织相容性复合物(mhc)ii类分子的基因修饰小鼠
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
KR102074145B1 (ko) 2011-10-28 2020-02-07 리제너론 파아마슈티컬스, 인크. 유전자 변형된 주요 조직적합성 복합체 마우스
KR102542272B1 (ko) * 2011-10-28 2023-06-13 리제너론 파아마슈티컬스, 인크. 유전자 변형된 ｔ 세포 수용체 마우스
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
PT2773671T (pt) 2011-11-04 2021-12-14 Zymeworks Inc Geração de anticorpo heterodimérico estável com mutações no domínio fc
US9547499B2 (en) 2011-12-09 2017-01-17 Microsoft Technology Licensing, Llc Device configuration with cached pre-assembled driver state
WO2013126726A1 (en) * 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
JP5920830B2 (ja) 2012-09-28 2016-05-18 シスメックス株式会社 試料調製装置および細胞分析装置
DK2840892T3 (en) 2013-02-20 2018-07-23 Regeneron Pharma Non-human animals with modified heavy chain immunoglobulin sequences
SI2958938T1 (sl) 2013-02-20 2019-08-30 Regeneron Pharmaceuticals, Inc. Miši, ki izražajo humanizirane koreceptorje za celice T
KR102211267B1 (ko) 2013-02-22 2021-02-04 리제너론 파아마슈티컬스, 인크. 사람화된 주요 조직적합성 복합체를 발현하는 마우스

Also Published As

Publication number Publication date
SG11201701040XA (en) 2017-03-30
BR112017005245A2 (pt) 2017-12-12
AU2015317370A1 (en) 2017-03-23
KR20170083534A (ko) 2017-07-18
IL250536A0 (en) 2017-03-30
RU2017113134A (ru) 2018-10-19
JP2017529841A (ja) 2017-10-12
CN107072184A (zh) 2017-08-18
EP3193592A1 (en) 2017-07-26
CA2959428A1 (en) 2016-03-24
US20160081314A1 (en) 2016-03-24
WO2016044745A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
MX2017003640A (es) Receptores antigenicos quimericos.
IL278879A (en) A chimeric antigen receptor having antigen-binding regions for the beta T-cell receptor constant region
CY1122831T1 (el) Υποκινητης μνd χιμαιρικων αντιγονικων υποδοχεων
EP3440191A4 (en) CHIMERIC ANTIGEN RECEPTOR T CELL LYMPHOCYTE COMPOSITIONS
IL272302A (en) Chimeric antigen receptor-mediated cell targeting
PT3443075T (pt) Células t transgénicas e composições de células t que expressam um recetor antigénico quimérico e métodos relacionados
MX2016012713A (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
MX2022000132A (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
IL250831A0 (en) Antibodies and chimeric antigen receptors specific for cd19, preparations containing them and their uses
NZ728555A (en) Bcma chimeric antigen receptors
DK3166968T3 (da) Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler
PL3294764T3 (pl) Kompozycje chimerycznego receptora antygenowego
BR112017011893A2 (pt) células t modificadas no receptor de antígeno quimérico direcionado para cs1
MY195115A (en) Antibodies targeting g-protein coupled receptor and methods of use
GB201607968D0 (en) Chimeric antigen receptor
HK1223123A1 (zh) 新穎抗人類 受體抗體
GB201610512D0 (en) Chimeric antigen receptor
ZA201906321B (en) Chimeric antigen receptor
IL266950B1 (en) γδ t cells expressing a chimeric antigen receptor for use in immunotherapy
GB201709508D0 (en) Chimeric antigen receptor
SG10202010600SA (en) T cell receptor like antibodies that bind to p53-mhc class i complex
GB201721831D0 (en) T cell antigen receptor chimera
GB201817676D0 (en) T cell antigen receptor chimera
AU2016902764A0 (en) Chimeric antigen receptor modified T cells
GB201721421D0 (en) Chimeric antigen receptor